{"denoms":[{"counts":[{"groupId":"BG000","value":"5"}],"units":"Participants"}],"groups":[{"description":"All patients were treated with the DexTR (dexamethasone / thalidomide, lenalidomide (Revlimid®)), which consisted of lenalidomide 25mg/day during days 1-21, dexamethasone 40mg/day on days 1-4, 9-12, and 17-20, and thalidomide 50mg/day for the first 7 days, followed by 100mg/day for all subsequent days, for a total of 4 cycles of 28 days each.\n\ndexamethasone: Cycles 1-4\n\n• Dexamethasone (40mg ) will be given on days 1-4, 9-12, 17-20 of a 28-day cycle.\n\nAfter completing 4 cycles:\n\n* Patients who demonstrate disease progression at any time will be taken off study.\n* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \\> 2 cycles will be transitioned to maintenance therapy.\n* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \\>2 cycles or CR in the absence of unt","id":"BG000","title":"DexTR (All Patients)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"50","upperLimit":"80","value":"65"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"3.1","upperLimit":"4.2","value":"3.8"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"serum creatinine at baseline (in mg/dL)","unitOfMeasure":"mg/dL"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1.5","upperLimit":"5.6","value":"4.1"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Beta-2 microglobulin at baseline (in mg/L)","unitOfMeasure":"mg/dL"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"150","upperLimit":"225","value":"177"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"lactage dehydrogenase at baseline (U/L)","unitOfMeasure":"U/L"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"1 (a or b)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"2a"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"2b"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"3a"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"3b"}],"description":"Subjects were staged according to the Durie salmon Staging Classification System. Criteria for the staging system can be found here: https://www.themmrf.org/multiple-myeloma/prognosis/myeloma-stages/durie-salmon-staging-system/.\n\nStaging classification describes multiple myeloma tumor burden; stage 1 is a low tumor burden/myeloma cell mass, stage 2 is intermediate tumor burden/cell mass, and stage 3 is a high tumor burden/cell mass.","paramType":"NUMBER","title":"Durie-Salmon Classification","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"III"}],"description":"Stage I: β2M \\< 3.5 mg/l and serum albumin ≥3.5 g/100 ml (median survival 62 months); stage II, neither stage I nor stage III (median survival 44 months) and stage III β2M ≥5.5 mg/l (median survival 29 months)","paramType":"NUMBER","title":"International Staging System Classification","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"IgG lambda Myeloma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Free Kappa light Chain Myeloma"}],"paramType":"NUMBER","title":"Immunoglobulins","unitOfMeasure":"participants"}]}